Roles of opioid receptor subtypes on the antinociceptive effect of intrathecal sildenafil in the formalin test of rats

Neuroscience Letters

Volumn 441, Issue 1, 2008, Pages 125-128

  Yoon, Myung Ha ^a   Kim, Woong Mo ^a   Lee, Hyung Gon ^a   Kim, Yeo Ok ^a   Huang, Lan Ji ^a   An, Tae Hoon ^b  

^a Chonnam National University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Antinociception; Formalin test; Opioid receptors; Sildenafil; Spinal cord; Sprague Dawley rat

Indexed keywords

5' GUANIDINYL 17 (CYCLOPROPYLMETHYL) 6,7 DEHYDRO 4,5ALPHA EPOXY 3,14 DIHYDROXY 6,7 2',3' INDOLOMORPHIAN; DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; FORMALDEHYDE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; NALTRINDOLE; PHOSPHODIESTERASE V; SILDENAFIL;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVITY; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PAIN THRESHOLD; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; SOMATOSTATIN; SULFONES; TIME FACTORS;

EID: 46149100223     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.06.011     Document Type: Article

References (22)

1. Araiza-Saldaña C.I., Reyes-García G., Bermúdez-Ocaña D.Y., Pérez-Severiano F., and Granados-Soto V. Effect of diabetes on the mechanisms of intrathecal antinociception of sildenafil in rats. Eur. J. Pharmacol. 527 (2005) 60-70
2. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
3. Boolell M., Gepi-Attee S., Gingell J.C., and Allen M.J. Sildenafil a novel effective oral therapy for male erectile dysfunction. Br. J. Urol. 78 (1996) 257-261
4. Chaturverdi K., Christoffers K.H., Singh K., and Howells R.D. Structure and regulation of opioid receptors. Biopolymers 55 (2000) 334-346
5. Deguchi T. Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. J. Biol. Chem. 252 (1977) 7617-7619
6. Duarte I.D., Lorenzetti B.B., and Ferreira S.H. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur. J. Pharmacol. 186 (1990) 289-293
7. Ferreira S.H., Duarte I.D., and Lorenzetti B.B. The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur. J. Pharmacol. 201 (1991) 121-122
8. 2+ dependent process. Prostaglandins 18 (1979) 179-190
9. 2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain. J. Pharmacol. Exp. Ther. 248 (1989) 73-80
10. Jain N.K., Patil C.S., Singh A., and Kulkarni S.K. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res. 909 (2001) 170-178
11. Jones R.M., and Portoghese P.S. 5′-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur. J. Pharmacol. 396 (2000) 49-52
12. Menéndez L., Juárez L., García V., Hidalgo A., and Baamonde A. Involvement of nitric oxide in the inhibition of bone cancer-induced hyperalgesia through the activation of peripheral opioid receptors in mice. Neuropharmacology 53 (2007) 71-80
13. Pagliaro P. Differential biological effects of products of nitric oxide (NO) synthase: it is not enough to say NO. Life Sci. 73 (2003) 2137-2149
14. Patil C.S., Singh V.P., and Kulkarni S.K. Peripheral central activation of nitric oxide-cyclic GMP pathway by sildenafil. Inflammopharmacology 13 (2005) 467-478
15. Portoghese P.S., Sultana M., and Takemori A.E. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J. Med. Chem. 363 (1990) 1714-1720
16. Pyne N.J., Arshavsky V., and Lochhead A. cGMP signal termination. Biochem. Soc. Trans. 24 (1996) 1019-1022
17. Snyder S.H., and Pasternak G.W. Historical review: opioid receptors. Trends Pharmacol. Sci. 24 (2003) 198-205
18. Sousa A.M., and Prado W.A. The dual effect of a nitric oxide donor in nociception. Brain Res. 897 (2001) 9-19
19. Ückert S., Hedlund P., Andersson K.E., Truss M.C., Jonas U., and Stief C.G. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur. Urol. 50 (2006) 1194-1207
20. Vale M.L., Rolim D.E., Cavalcante I.F., Ribeiro R.A., and Souza M.H. Role of NO/cGMP/K(ATP) pathway in antinociceptive effect of sildenafil in zymosan writhing response in mice. Inflamm. Res. 56 (2007) 83-88
21. Yaksh T.L., and Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17 (1976) 1031-1036
22. Yoon M.H., Park K.D., Lee H.G., Kim W.M., An T.H., Kim Y.O., Huang L.J., and Cui J.H. Additive antinociception between intrathecal sildenafil and morphine in the rat formalin test. J. Korean Med. Sci. 6 (2008)